抗NSG1自身抗体联合CEA、CYFRA21-1和SCC-Ag用于食管鳞癌诊断的panel开发
该研究通过免疫组化检测40对食管鳞癌(ESCC)及癌旁组织中NSG1蛋白表达,并用ELISA检测203例早期ESCC、103例晚期ESCC、135例食管良性病变(EBL)和155例健康对照(HCs)的血清抗NSG1水平。结果显示ESCC组血清抗NSG1显著高于EBL和HC组(p<0.001),其诊断ESCC的AUC为0.706(灵敏度49.7%,特异度93.5%),优于CEA、CYFRA21-1和SCC-Ag;抗NSG1与三者联合的AUC最高达0.758(灵敏度67.3%,特异度88.3%),NPV最高71.9%,NLR最低0.37。
要点
- 血清抗NSG1在ESCC患者中显著升高,诊断AUC为0.706,优于传统标志物。
- 抗NSG1联合CEA、CYFRA21-1和SCC-Ag可将AUC提升至0.758。
- 联合panel的灵敏度67.3%、特异度88.3%,NPV 71.9%,NLR 0.37。
核心结论
- ESCC组织中NSG1蛋白表达异常可能促使血清中抗NSG1自身抗体大量释放。
- 抗NSG1与CEA、CYFRA21-1和SCC-Ag联合有助于进一步提高ESCC的诊断效能。
研究设计与样本
- 免疫组化检测40对ESCC组织及配对癌旁组织中NSG1蛋白表达。
- ELISA检测203例早期ESCC、103例晚期ESCC、135例EBL和155例HCs的血清抗NSG1水平。
- 评估血清抗NSG1与CEA、CYFRA21-1和SCC-Ag所有可能组合对ESCC的诊断性能。
主要发现
- ESCC组织中NSG1蛋白表达显著高于配对癌旁组织(p<0.001)。
- ESCC组血清抗NSG1显著高于EBL组和HC组(p<0.001)。
- 血清抗NSG1诊断ESCC的AUC为0.706,灵敏度49.7%,特异度93.5%,优于CEA、CYFRA21-1和SCC-Ag。
- 抗NSG1联合CEA、CYFRA21-1和SCC-Ag的AUC最高为0.758,灵敏度67.3%,特异度88.3%,NPV最高71.9%,NLR最低0.37。
关键数值与推荐
- 血清抗NSG1诊断ESCC:AUC 0.706,灵敏度49.7%,特异度93.5%。
- 抗NSG1联合CEA、CYFRA21-1和SCC-Ag诊断ESCC:AUC 0.758,灵敏度67.3%,特异度88.3%,NPV 71.9%,NLR 0.37。
临床怎么用
- 血清抗NSG1可作为ESCC诊断的候选血清学标志物。
- 抗NSG1联合CEA、CYFRA21-1和SCC-Ag可能提高ESCC的诊断效率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Development of a panel of serum autoantibody against Neuron specific gene family member 1 (NSG1) with traditional tumor biomarkers of esophageal squamous cell carcinoma (ESCC) to further improve the diagnostic efficiency for ESCC patients. METHODS: Immunohistochemistry (IHC) staining was used to detect the expression of NSG1 protein in 40 pairs of ESCC tissues and matched paracancerous tissues. Serum anti-NSG1 levels of 203 patients with early ESCC, 103 patients with advanced ESCC, 135 patients with esophageal benign lesion (EBL), and 155 healthy controls (HCs) were detected by ELISA. The diagnostic performances of all possible combinations of serum anti-NSG1with CEA, CYFRA21-1 and SCC-Ag were assessed to develop an optimal panel for ESCC diagnosis. RESULTS: NSG1 protein expression in ESCC tissues was significantly higher than that in matched paracancerous tissues (p < 0.001). Serum anti-NSG1 expression in ESCC group was significantly higher than that in EBL group and HC group (p < 0.001). The AUC of serum anti-NSG1 for ESCC was 0.706, with 49.7% sensitivity at 93.5% specificity, superior to that of CEA, CYFRA21-1 and SCC-Ag. Of all possible combinations, serum anti-NSG1 combined with CEA, CYFRA21-1 and SCC-Ag showed the highest AUC of 0.758 and 67.3% sensitivity at 88.3% specificity for ESCC, with the highest NPV of 71.9% and the lowest NLR of 0.37. CONCLUSION: Aberrant NSG1 protein expression in ESCC tissues might be responsible for massive releases of autoantibody anginst NSG1 in sera of ESCC. A panel of anti-NSG1 with CEA, CYFRA21-1 and SCC-Ag contributes to further improving the diagnostic efficiency for ESCC.
引用
- Zheng Q, Zhang L, Tu M, et al. Development of a panel of autoantibody against NSG1 with CEA, CYFRA21-1, and SCC-Ag for the diagnosis of esophageal squamous cell carcinoma. Clin Chim Acta. 2021. PMID: 34119530. doi:10.1016/j.cca.2021.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。